Key takeaway
In a 23-person crossover pilot, a personalized diet built to limit predicted glucose spikes lowered average post-meal glucose by 19.8 mg/dl × h more than a Mediterranean-style diet (p < 0.001) over 2 weeks. The trial is tiny, short and its 6-month extension had no control group, so the 61% remission figure should be read cautiously.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Diet is the first-line approach for newly diagnosed type 2 diabetes, yet many people do not reach their goals with it. The authors tested whether a diet personalized to predicted blood glucose responses works better than a commonly recommended Mediterranean-style diet.
Who and how
Randomized crossover pilot trial in 23 adults with newly diagnosed type 2 diabetes (aged 53.5 ± 8.9 years, 48% male). Participants, blinded to sequence, followed a personalized postprandial-targeting (PPT) diet and a Mediterranean-style (MED) diet for 2 weeks each, in either order. The PPT diet used a machine learning algorithm combining clinical and microbiome features to predict each person's postprandial glucose response (PPGR). 16 participants continued the PPT diet for another 6 months. Continuous glucose monitoring (CGM) ran throughout and diet was self-recorded in a smartphone app.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1On the PPT diet, average PPGR was lower than on the MED diet by 19.8 ± 16.3 mg/dl × h (p < 0.001), mean glucose by 7.8 ± 5.5 mg/dl (p < 0.001), and daily time above 140 mg/dl by 2.42 ± 1.7 h/day (p < 0.001).
- 2Blood fructosamine fell more during PPT than MED (mean change difference −16.4 ± 37 μmol/dl, p < 0.0001).
- 3After 6 months of PPT (n = 16), HbA1c fell by 0.39 ± 0.48% (p < 0.001), fasting glucose by 16.4 ± 24.2 mg/dl (p = 0.02) and triglycerides by 49 ± 46 mg/dl (p < 0.001).
- 461% of participants had diabetes remission, defined as HbA1c < 6.5%.
- 5Some clinical improvements were associated with gut microbiome changes within individuals.
Limits & uncertainty
- 1Only 23 participants in the crossover phase and 16 in the extension, so estimates are imprecise.
- 2The 6-month phase had no comparison group, so the HbA1c, glucose, triglyceride changes and remission cannot be attributed to the PPT diet alone.
- 3The crossover phases lasted only 2 weeks each, and the abstract does not report whether effects carried over between periods.
- 4The PPT diet depends on clinical and microbiome data and a proprietary algorithm, which limits how easily it can be copied; this reading is based on the abstract only.
What to take from it
The results suggest that people differ in how their glucose responds to the same food, and that tailoring food choices to those responses may help. This was a small pilot, so it does not show that a personalized diet beats other diets in general. Anyone with diabetes should plan diet and medication with their clinician.
Reading your own data
If you wear a CGM or log meals, you can compare your own post-meal glucose rises for different foods, using the same sensor and similar timing. Look at repeated patterns across several days rather than one reading.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Dietary modifications are crucial for managing newly diagnosed type 2 diabetes mellitus (T2DM) and preventing its health complications, but many patients fail to achieve clinical goals with diet alone. We sought to evaluate the clinical effects of a personalized postprandial-targeting (PPT) diet on glycemic control and metabolic health in individuals with newly diagnosed T2DM as compared to the commonly recommended Mediterranean-style (MED) diet.
Methods
We enrolled 23 adults with newly diagnosed T2DM (aged 53.5 ± 8.9 years, 48% males) for a randomized crossover trial of two 2-week-long dietary interventions. Participants were blinded to their assignment to one of the two sequence groups: either PPT-MED or MED-PPT diets. The PPT diet relies on a machine learning algorithm that integrates clinical and microbiome features to predict personal postprandial glucose responses (PPGR). We further evaluated the long-term effects of PPT diet on glycemic control and metabolic health by an additional 6-month PPT intervention (n = 16). Participants were connected to continuous glucose monitoring (CGM) throughout the study and self-recorded dietary intake using a smartphone application.
Results
In the crossover intervention, the PPT diet lead to significant lower levels of CGM-based measures as compared to the MED diet, including average PPGR (mean difference between diets, - 19.8 ± 16.3 mg/dl × h, p < 0.001), mean glucose (mean difference between diets, - 7.8 ± 5.5 mg/dl, p < 0.001), and daily time of glucose levels > 140 mg/dl (mean difference between diets, - 2.42 ± 1.7 h/day, p < 0.001). Blood fructosamine also decreased significantly more during PPT compared to MED intervention (mean change difference between diets, - 16.4 ± 37 μmol/dl, p < 0.0001). At the end of 6 months, the PPT intervention leads to significant improvements in multiple metabolic health parameters, among them HbA1c (mean ± SD, - 0.39 ± 0.48%, p < 0.001), fasting glucose (- 16.4 ± 24.2 mg/dl, p = 0.02) and triglycerides (- 49 ± 46 mg/dl, p < 0.001). Importantly, 61% of the participants exhibited diabetes remission, as measured by HbA1c < 6.5%. Finally, some clinical improvements were significantly associated with gut microbiome changes per person.
Conclusion
In this crossover trial in subjects with newly diagnosed T2DM, a PPT diet improved CGM-based glycemic measures significantly more than a Mediterranean-style MED diet. Additional 6-month PPT intervention further improved glycemic control and metabolic health parameters, supporting the clinical efficacy of this approach.
Trial registration
ClinicalTrials.gov number, NCT01892956.
Sources & attribution
Effects of personalized diets by prediction of glycemic responses on glycemic control and metabolic health in newly diagnosed T2DM: a randomized dietary intervention pilot trial.
Rein M, Ben-Yacov O, Godneva A, Shilo S, Zmora N, Kolobkov D, Cohen-Dolev N, Wolf BC, Kosower N, Lotan-Pompan M, Weinberger A, Halpern Z, Zelber-Sagi S, Elinav E, Segal E.
BMC medicine · 2022-02-09
DOI: 10.1186/s12916-022-02254-y ↗PubMed · 35135549 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

